Delivra Health Brands (DHB) Q2 2026 earnings summary

Executive summary

• Year-to-date e-commerce sales grew 26% for Dream Water and 28% for LivRelief, offset by declines in retail sales for both brands compared to the same period last year.

• Total net revenue for Q2 2026 was $2,433, down 12% year-over-year, mainly due to lower retail sales and distribution channel transitions.

• Management is focused on stabilizing retail ordering, reigniting growth in licensed markets, and expanding high-margin direct-to-consumer and U.S. retail channels.

Financial highlights

• Q2 2026 net revenue: $2,433 (down 12% year-over-year); six-month net revenue: $5,640 (down 5% year-over-year).

• Q2 2026 gross profit: $972 (margin 40%), down from $1,294 (margin 47%) last year; six-month gross profit: $2,473 (margin 44%), down from $2,891 (margin 49%).

• Q2 2026 Adjusted EBITDA: $(369), compared to $(194) last year; six-month Adjusted EBITDA: $(313), compared to $(176) last year.

• Q2 2026 SG&A expenses: $1,391, down 10% year-over-year, mainly due to reduced marketing spend.

• Net loss from continued operations for Q2 2026: $(411), or $(0.01) per share; six-month net loss: $(502), or $(0.02) per share.

Outlook and guidance

• Management expects to stabilize retail ordering patterns and resume growth in licensed markets in the second half of fiscal 2026 and fiscal 2027.

• Focus remains on expanding high-margin direct-to-consumer and U.S. retail opportunities.